olivLaw · US equity research
Fractyl Health, Inc. GUTS
Surgical & Medical Instruments & Apparatus · SIC 3841 · Vertical: Surgical & Medical Instruments & Apparatus (SIC 3841)
Fractyl Health develops metabolic therapies for obesity and type 2 diabetes, centered on Revita, a endoscopic procedure meant to sustain weight loss after GLP-1 drugs are stopped, and the Rejuva gene therapy platform. The company is still in clinical stage with no product approved for U.S. sale, and its losses and funding needs remain decisive, with a net loss of 141.0 million USD reported for 2025.
At the close of 04 Nov 2026, Fractyl Health, Inc. (GUTS) stock was 0.97 USD (+8.30% on the day), with market capitalisation 154.8 m USD, beta 1.21, 52-week range 0.88–28.44 USD. Latest reported quarter (Q2 2026): net income of -25.5 m USD, diluted EPS -0.16 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 18.7
- oversold (≤ 30)
- Bollinger (20, 2)
- -0.87 – 4.92
- in the lower half of the band · %B 0.32 · band width 285.4%
- SMA 50 / 200
- 4.96 / 7.54
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -1.23 / -1.33
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −78.7% | −1.1% | −77.6 pp | — |
| 3 months | −88.2% | −0.5% | −87.7 pp | — |
| 6 months | −89.0% | +4.4% | −93.4 pp | — |
| Year to date | −96.3% | +12.3% | −108.6 pp | — |
| 1 year | −92.8% | +13.5% | −106.3 pp | −5.2% |
| 3 years | unavailable | +76.4% | unavailable | +14.6% |
| 5 years | unavailable | +63.7% | unavailable | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14.0 k | 3.0 k | — | — | — | — | — | — |
| Cost of revenue | 7.0 k | 0 | — | — | — | — | — | — |
| Gross profit | 7.0 k | 3.0 k | — | — | — | — | — | — |
| Research & development | 19.0 m | 20.3 m | 19.4 m | 21.2 m | 17.5 m | 16.5 m | 15.6 m | 13.8 m |
| SG&A | 4.8 m | 4.9 m | 5.3 m | 4.9 m | 5.2 m | 6.8 m | 5.2 m | 5.3 m |
| Operating income | -23.8 m | -25.2 m | -24.8 m | -26.1 m | -22.7 m | -23.3 m | -20.8 m | -19.1 m |
| Net income | -23.2 m | -25.0 m | -23.7 m | -27.9 m | -45.6 m | -43.7 m | 9.2 m | -25.5 m |
| Diluted EPS | -0.48 | -0.52 ≈ | -0.49 | -0.57 | -0.71 | -0.31 ≈ | 0.06 | -0.16 |
| Operating cash flow | -18.0 m ≈ | -17.0 m | -25.1 m | -21.2 m ≈ | -22.7 m ≈ | -21.3 m | -22.5 m | -15.9 m ≈ |
| Capex | 213.0 k ≈ | 233.0 k | 448.0 k | 98.0 k ≈ | 8.0 k ≈ | 3.0 k | — | — |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 120.0 k | 93.0 k | 0 |
| Revenue YoY | unavailable | −22.5% | −100.0% |
| Net income | -77.1 m | -68.7 m | -141.0 m |
| Net income YoY | unavailable | unavailable | unavailable |
| Diluted EPS | -45.29 | -1.62 | -1.86 |
| Diluted EPS YoY | unavailable | unavailable | unavailable |
| net % | -64,242.5% | -73,864.5% | unavailable |
| Free cash flow | -43.2 m | -67.3 m | -90.9 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 81.5 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 9.5 m USD
- Total assets
- 121.4 m USD
- Debt / equity
- unavailable
- Current ratio
- 4.78x
- ROE
- -744.2%
- ROA
- -122.8%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Revenue | 120.0 k | 93.0 k | 0 | SEC (XBRL)· 24 Mar 2026verified |
| Cost of revenue | 77.0 k | 50.0 k | 0 | SEC (XBRL)· 24 Mar 2026verified |
| Gross profit | 43.0 k | 43.0 k | 0 ≈ | SEC (XBRL)· 24 Mar 2026derived |
| Research & development | 38.0 m | 70.5 m | 74.5 m | SEC (XBRL)· 24 Mar 2026verified |
| SG&A | 12.8 m | 23.1 m | 22.3 m | SEC (XBRL)· 24 Mar 2026verified |
| Operating income | -50.8 m | -93.5 m | -96.8 m | SEC (XBRL)· 24 Mar 2026verified |
| Income tax | 0 | 0 | 0 | SEC (XBRL)· 24 Mar 2026verified |
| Net income | -77.1 m | -68.7 m | -141.0 m | SEC (XBRL)· 24 Mar 2026verified |
| Diluted EPS | -45.29 | -1.62 | -1.86 | SEC (XBRL)· 24 Mar 2026verified |
| Weighted average diluted shares | 2.1 m | 43.5 m | 75.8 m | SEC (XBRL)· 24 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Revenue − Cost of revenue.
Balance sheet · USD
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Cash | 33.2 m | 67.5 m | 81.5 m | SEC (XBRL)· 24 Mar 2026verified |
| Receivables | 22.0 k | 0 | — | SEC (XBRL)· 03 Mar 2025verified |
| Inventories | 73.0 k | 73.0 k | — | SEC (XBRL)· 03 Mar 2025verified |
| Current assets | 35.6 m | 71.8 m | 87.6 m | SEC (XBRL)· 24 Mar 2026verified |
| Property, plant & equipment, net | 490.0 k | 3.0 m | 2.4 m | SEC (XBRL)· 24 Mar 2026verified |
| Total assets | 76.2 m | 108.1 m | 121.4 m | SEC (XBRL)· 24 Mar 2026verified |
| Accounts payable | 553.0 k | 3.2 m | 1.6 m | SEC (XBRL)· 24 Mar 2026verified |
| Current liabilities | 11.2 m | 19.8 m | 18.3 m | SEC (XBRL)· 24 Mar 2026verified |
| Total liabilities | 113.9 m | 79.7 m | 111.9 m | SEC (XBRL)· 24 Mar 2026verified |
| Equity | -325.1 m † | 28.4 m † | 9.5 m † | SEC (XBRL)· 24 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Operating cash flow | -42.8 m | -65.5 m | -90.3 m | SEC (XBRL)· 24 Mar 2026verified |
| Capex | 359.0 k | 1.8 m | 557.0 k | SEC (XBRL)· 24 Mar 2026verified |
| Free cash flow | -43.2 m ≈ | -67.3 m ≈ | -90.9 m ≈ | SEC (XBRL)· 24 Mar 2026derived |
| Investing cash flow | -359.0 k | -1.8 m | -557.0 k | SEC (XBRL)· 24 Mar 2026verified |
| Financing cash flow | 27.4 m | 101.2 m | 105.0 m | SEC (XBRL)· 24 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 2 of at least 6
- score weight coverage: 12.5% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 154.8 m USD
Key indicators
Coverage and freshness
Score by group
13% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 2 of at least 6; score weight coverage: 12.5% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | unavailable | unavailable | — |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 3.2x | 100 (on a fixed band) | 33% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -53.6% | 0 (on a fixed band) | 67% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partialunavailable · 0/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Fractyl Health, Inc. (GUTS). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 0 USD in 2025; YoY growth -100.0%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 2 of at least 6; score weight coverage: 12.5% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 3.2x
What contradicts it
- FCF yield: -53.6%
Not assessed (insufficient data or a ratio without meaning): ROIC, Net margin, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Surgical & Medical Instruments & Apparatus (SIC 3841) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| SYKStryker Corp | 129.3 bn | 36.2 | 16.0% | 13.8% | +11.2% | −8% / +15% |
| MMM3m Company | 100.2 bn | 28.9 | 80.8% | 14.0% | +1.5% | +13% / +134% |
| BSXBoston Scientific Corporation | 66.4 bn | 19.4 | 14.3% | 16.6% | +19.9% | −55% / −18% |
| BDXBecton, Dickinson And Company | 57.0 bn | 63.2 | 3.8% | 4.0% | +8.2% | +37% / +13% |
| RMDResMed Inc. | 33.8 bn | 21.9 | 26.4% | 27.8% | +9.9% | −6% / +52% |
| DXCMDexcom, Inc. | 33.0 bn | 34.8 | 37.7% | 19.4% | +15.6% | +39% / −23% |
| WSTWest Pharmaceutical Services, Inc. | 28.5 bn | 45.9 | 21.2% | 18.8% | +6.3% | +47% / +17% |
| SOLVSolventum Corporation | 15.2 bn | 10.9 | 34.0% | 17.3% | +0.9% | +5% / unavailable |
| PENPenumbra, Inc | 12.7 bn | 81.2 | 10.7% | 10.1% | +17.5% | +10% / +45% |
| GMEDGlobus Medical, Inc. | 11.7 bn | 22.3 | 11.8% | 17.0% | +16.7% | −4% / +94% |
| TFXTeleflex Incorporated | 6.4 bn | — | -28.9% | -45.8% | +17.2% | +31% / −34% |
| HAEHaemonetics Corporation | 5.8 bn | 62.3 | 11.2% | 7.1% | −2.0% | +57% / +58% |
| MMSIMerit Medical Systems Inc | 5.4 bn | 34.0 | 9.8% | 9.9% | +11.8% | +5% / +27% |
| HTFLHeartflow, Inc. | 4.9 bn | — | — | -55.8% | +39.9% | +75% / unavailable |
| ICUIIcu Medical Inc | 4.3 bn | 144.2 | 1.4% | 1.4% | −6.3% | +16% / +97% |
| LMATLemaitre Vascular, Inc. | 2.0 bn | 30.9 | 16.8% | 25.0% | +13.5% | +6% / +67% |
| TNDMTandem Diabetes Care, Inc. | 1.3 bn | — | -48.0% | -6.1% | +7.9% | −9% / −6% |
| IARTIntegra Lifesciences Holdings Corp | 1.2 bn | 88.3 | 1.2% | 0.8% | +1.5% | +13% / −62% |
| BBNXBeta Bionics, Inc. | 921.5 m | — | -23.9% | -65.3% | +53.9% | −46% / unavailable |
| SSIISs Innovations International, Inc. | 454.9 m | — | -26.1% | -23.7% | +105.7% | −66% / unavailable |
| CARLCarlsmed, Inc. | 439.3 m | — | -6,196.9% | -57.4% | +85.9% | −1% / unavailable |
| BWAYBrainsway Ltd. | 439.0 m | 224.2 | 5.6% | 7.1% | +29.0% | +28% / +258% |
| EMBCEmbecta Corp. | 369.4 m | 4.4 | — | 8.6% | −3.8% | −49% / −64% |
| CLPTClearPoint Neuro, Inc. | 325.7 m | — | -167.5% | -79.4% | +17.8% | −30% / +76% |
| TMCITreace Medical Concepts, Inc. | 292.7 m | — | -72.0% | -29.0% | +1.6% | +51% / −49% |
1- and 3-year price returns: for GUTS from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Fractyl Health develops metabolic therapies for obesity and type 2 diabetes, centered on Revita, a endoscopic procedure meant to sustain weight loss after GLP-1 drugs are stopped, and the Rejuva gene therapy platform. The company is still in clinical stage with no product approved for U.S. sale, and its losses and funding needs remain decisive, with a net loss of 141.0 million USD reported for 2025 1.
SWOT
Strengths
- The company pioneers an approach that targets the organ-level causes of metabolic disease, and its Revita program holds Breakthrough Device designation.
- One-year data from REVEAL-1 and the REMAIN-1 Midpoint Cohort show sustained weight maintenance and a favorable safety profile.
- The leadership team combines product development, therapeutic and commercial readiness experience, and the company recently strengthened its market access function.
Weaknesses
- The company has no product approved for U.S. sale and generated no product revenue in 2025.
- Substantial doubt about the ability to continue as a going concern exists, and net losses remain significant.
- Some results are descriptive rather than statistically powered, and the cohorts are small, which limits generalization.
Opportunities
- A positive pivotal study result and a possible De Novo clearance could open access to a very large market.
- A U.S. distribution partnership could speed adoption at high-volume endoscopy centers.
- Early human data from RJVA-001 could extend the value of the Rejuva platform beyond Revita.
Threats
- GLP-1 medicines and new obesity therapies could reduce the appeal of a procedure for weight maintenance.
- Payor coverage and reimbursement for the procedure remain uncertain and could delay adoption.
- If additional funding is not secured in time, the company could be forced to cut or suspend programs.
Risks
- Financing and going concernhigh
The company has identified conditions that raise substantial doubt about its ability to continue as a going concern. Without additional funding, it could be forced to reduce development programs, and failing the minimum liquidity covenant of its 2023 Notes could have consequences.
- Outcome of the pivotal studyhigh
Six-month topline data from the REMAIN-1 Pivotal Cohort are expected in early Q4 2026. An unfavorable result could delay or jeopardize the planned De Novo submission.
- Regulatory timelinemedium
The regulatory pathway is not yet finalized, and the FDA will set the final pathway after reviewing the full safety dataset. Additional requirements could arise and delay approval.
- Reimbursement and adoptionmedium
Even after approval, commercial success depends on coverage from CMS and insurers. A lack of clear reimbursement could limit adoption of the procedure.
- Dependence on a single proceduremedium
Revita is the main product, and some programs have already been paused. If results do not support an expanded indication, the company's value could decline significantly.
Investment thesis
What would need to be true (bull case)
- If pivotal data confirm weight maintenance and the FDA accepts the De Novo submission, the company could have its first commercial product in a very large market.
- The effect seen in subgroups with complete duodenal ablation suggests the method could be optimized, which could increase clinical efficacy.
- The Rejuva platform offers a second growth path, and early human data could validate the gene therapy approach beyond Revita.
What would break the thesis
- The company has no product revenue and depends on outside financing, and if capital is not available in time, projects could be reduced.
- Results reported so far come from small cohorts, and some analyses are descriptive, which could make the evidence harder for regulators to accept.
- GLP-1 medicines are evolving quickly, and a cheaper or more convenient alternative could reduce interest in an invasive procedure.
What to watch
- Six-month topline data from the REMAIN-1 Pivotal Cohortearly Q4 2026
- Possible submission of the De Novo application to the FDAlate Q4 2026
- One-year topline data from the REMAIN-1 Pivotal CohortQ1 2027
- Additional funding and liquidity, including the 2023 Notes minimum liquidity covenant2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Fractyl Health is a clinical-stage company based in Burlington, Massachusetts, aiming to treat the root causes of obesity and type 2 diabetes rather than only their symptoms. Its main product, the Revita DMR System, remodels the duodenal lining through hydrothermal ablation, with the goal of restoring nutrient sensing and supporting weight maintenance after GLP-1 therapy is discontinued 1. Besides Revita, the company develops Rejuva, a locally administered pancreatic gene therapy whose lead candidate, RJVA-001, received clinical trial authorization in the Netherlands 2. The company has not generated U.S. product revenue, and the only commercial activity mentioned is a pilot launch in Germany whose investment has been paused 1.
Strategy was reprioritized in early 2025: investment in Revita programs for type 2 diabetes was paused and the company reduced its workforce by approximately 17% 1. Focus has shifted to the REMAIN-1 study evaluating weight maintenance after GLP-1 therapy and to preparing a possible FDA De Novo submission. The company intends to build a sales force oriented toward gastroenterologists with an interest in bariatric and metabolic endoscopy 1.
Financially, the company reports continuing net losses and has identified conditions that raise substantial doubt about its ability to continue as a going concern 1. Management estimates that available resources at mid-2026 will fund operations into early 2027, which covers the 2026 clinical milestones but not necessarily the commercial launch 2.
Segments
Revita (obesity and weight maintenance)
Revita is the lead candidate, holding FDA Breakthrough Device designation for weight maintenance in people with obesity who discontinue GLP-1 therapy 1. One-year data from REVEAL-1 and the REMAIN-1 Midpoint Cohort support the effect, but these are descriptive results from small cohorts 23.
Market context
The company describes a very large market, with about 115 million people in the U.S. having prediabetes and/or obesity, and industry expectations of roughly 250 billion USD in obesity drug sales by the end of the decade 1. Over half of patients who start GLP-1 drugs discontinue within three months, which creates demand for weight maintenance solutions 1.
The market is highly competitive, and procedure adoption would depend on payor coverage and on integration into endoscopist workflows. The company has set out to build market access infrastructure, and it plans to present its commercial strategy at an investor day 3.
Trends
- Rising use of GLP-1 medicinestailwind
GLP-1 use is growing quickly, which increases the need for treatments that sustain results after these drugs are stopped. If this trend continues, demand for solutions such as Revita could grow.
- High discontinuation ratestailwind
Early discontinuation of GLP-1 therapy often leads to weight regain, which supports the company's thesis. It also suggests that patients and physicians are still looking for validated solutions.
- Reimbursement and clinical evidence requirementsheadwind
Procedure adoption depends on obtaining coverage from CMS and private insurers. If randomized evidence is not convincing enough, access to reimbursement could be delayed.
- Biotech financing environmentmixed
Companies without revenue depend on outside capital, and financing conditions can shape project timelines. Additional funding could be easier to obtain after positive study results, but this is not assured.
Competitive position
The company faces GLP-1 medicines and other therapies that are redefining obesity treatment, as well as other invasive and genetic approaches. The stated advantage of Revita is a single intervention that does not require daily or weekly dosing 1.
The Rejuva platform competes with other type 2 diabetes therapies, and its differentiation rests on local delivery and nutrient-responsive regulation. The company notes that its preclinical data compared favorably with semaglutide 1.
- Eli Lilly (tirzepatide)LLY
Named in the source through the SURMOUNT-4 study of tirzepatide, which shows weight regain after discontinuation.
- Novo Nordisk (semaglutide)
Named in the source through the STEP-1 study and through semaglutide, used as the comparator in Rejuva preclinical studies.
- Everself (formerly Bariendo)
A potential partner with which the company has a letter of intent for distributing endoscopic procedures across U.S. hospitals and centers.
- GLP-1 therapies in general
The drug class that dominates obesity treatment and whose role in weight maintenance the company disputes.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Fractyl Health shares rise 2.8% ahead of Virtual Commercial Strategy DayYahoo Finance — News · 01 Sept 2026 · EN
The latest news item in our archive is from 01 Sept 2026; the newest SEC filing is from 22 Oct 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Current report22 Oct 2026Exit or disposal costs · Departure or appointment of officers · Other events · Financial statements and exhibits
- Current report16 Oct 2026Regulation FD disclosure · Other events · Financial statements and exhibits
- Current report01 Oct 2026Amendments to articles or bylaws · Financial statements and exhibits
- Current report24 Sept 2026Shareholder vote
- Current report11 Sept 2026Delisting notice
- Proxy statement24 Aug 2026
- Quarterly report10 Aug 2026
- Current report10 Aug 2026Results of operations · Financial statements and exhibits
- Current report15 Jul 2026Regulation FD disclosure · Other events · Financial statements and exhibits
- Current report11 Jun 2026Shareholder vote
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Fractyl Health, Inc. · 24 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Fractyl Health, Inc. · 10 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Fractyl Health, Inc. · 10 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.